Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 7:02 PM
Ignite Modification Date: 2025-12-25 @ 4:35 PM
NCT ID: NCT01571557
Description: All enrolled patients were used to assess AEs and SAEs.
Frequency Threshold: 5
Time Frame: Adverse events (AEs) and serious adverse events (SAEs) were collected from the time of the first OZURDEX® injection through the final follow-up visit for each patient.
Study: NCT01571557
Study Brief: A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
OZURDEX® OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care. None None 1 573 33 573 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Glaucoma SYSTEMATIC_ASSESSMENT Eye disorders MedDRA version 16.1 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Intraocular Pressure Increased SYSTEMATIC_ASSESSMENT Eye disorders MedDRA version 16.1 View